glp-1 receptor agonist transdermal patch Scientists rethink delivery to improve dosing, tolerability, and adherence GLP-1 receptor assay: drug discovery
Description
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme
Eli Lilly is due to submit orforglipron for Type 2 diabetes to the FDA later this year
Yes, by improving cell response to insulin
Ben elaborates on this change: For the last 2,400 years, you would go to see somebody who was the medical doctor, and the diagnostic part was always the most important theme
Inference of macromolecular assemblies from crystalline state
